Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Second Sight Medical Products's enterprise value is $0.00 Mil.
Second Sight Medical Products's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-9.08 Mil. Therefore, Second Sight Medical Products's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Second Sight Medical Products's EV-to-EBITDA or its related term are showing as below:
EYESW'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.36 Med: -2.79 Max: 0.2
Current: 0.2
During the past 10 years, the highest EV-to-EBITDA of Second Sight Medical Products was 0.20. The lowest was -38.36. And the median was -2.79.
EYESW's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 14.415
vs EYESW: 0.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Second Sight Medical Products (NAS:EYESW) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Second Sight Medical Products's PE Ratio (TTM) for today is calculated as:
Second Sight Medical Products's share price for today is $0.2198.
Second Sight Medical Products's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EYESW vs SONX, LUCD, LHDX: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Second Sight Medical Products's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Second Sight Medical Products EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Second Sight Medical Products's EV-to-EBITDA falls into.
Second Sight Medical Products's current Enterprise Value is $0.00 Mil.
Second Sight Medical Products's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Second Sight Medical Products (EYESW) has a EV-to-EBITDA of 0.00 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Second Sight Medical Products.
Is Second Sight Medical Products' EV-to-EBITDA too high?
Second Sight Medical Products' current EV-to-EBITDA is 0.00.
How does Second Sight Medical Products' EV-to-EBITDA compare to SONX and LUCD?
Second Sight Medical Products' EV-to-EBITDA of 0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-EBITDA is 14.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.42, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Second Sight Medical Products. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Second Sight Medical Products's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Second Sight Medical Products stock overvalued right now?
Second Sight Medical Products (EYESW) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Second Sight Medical Products (EYESW), the current EV-to-EBITDA is 0.00 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EYESW has been successfully added to your 
